PITTSBURGH (AP) – Mylan Inc. said it will start selling a generic version of Novartis AG’s Vivelle-Dot estrogen patch in late 2013.
Mylan said it settled a patent lawsuit filed by Novartis Pharmaceuticals. Novartis will grant Mylan a license to start selling a generic version of Vivelle-Dot by Dec. 16, 2013. It said U.S. sales of the patch totaled $240 million over the 12 months ended Sept. 30.
Mylan asked the Food and Drug Administration to approve a generic version of the patch in March. The brand-name version is marketed by Novartis and Noven Pharmaceuticals Inc.
Date: November 21, 2011
Source: Associated Press
